Publications - Page 31 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Dyskinésies ciliaires primitives (DCP) 02/08/23
Breath-holding and tidal breathing nasal NO to screen children for Primary Ciliary Dyskinesia

Beydon N, Tamalet A, Escudier E, Legendre M, Thouvenin G.

Pediatr Pulmonol. 2021 Jul;56(7):2242-2249
Dyskinésies ciliaires primitives (DCP) 02/08/23
Motile cilia and airway disease

Legendre M, Zaragosi LE, Mitchison HM.

Semin Cell Dev Biol. 2021 Feb;110:19-33
Fibrose pulmonaire - FPI 02/08/23
Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study

Manali ED, Kannengiesser C, Borie R, Ba I, Bouros D, Markopoulou A, Antoniou K, Kolilekas L, Papaioannou AI, Tzilas V, Tzouvelekis A, Daniil Z, Fouka E, Papakosta D, Xyfteri A, Karakatsani A, Loukides S, Korbila I, Tomos IP, Konstantinidis AK, Gogali A, Steiropoulos P, Papanikolaou IC, Bazaka C, Haritou A, Vassilakopoulos T, Maniati M, Kagouridis K, Markozannes E, Bouros E, Rampiadou C, Kounti G, Trachalaki A, Dimeas I, Karampitsakos T, Lyberopoulos P, Malamadakis N, Spyropoulou S, Revy P, Lainey E, Dieudé P, Rebah K, Ménard C, Oudin C, Masson C, Plessier A, Legendre M, Nathan N, Coulomb-L'Hermine A, Clement A, Amselem S, Boileau C, Crestani B, Papiris S; Greek Group of ILD Investigators.

Respiration. 2022 Jan 25:1-13
Fibrose pulmonaire - FPI 02/08/23
Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort

Cottin V, Gueguen S, Jouneau S, Nunes H, Crestani B, Bonniaud P, Wémeau-Stervinou L, Reynaud-Gaubert M, Israël-Biet D, Cadranel J, Marchand-Adam S, Quétant S, Hirschi S, Montani D, Gamez AS, Chevereau M, Dufaure-Garé I, Amselem S, Clement A; OrphaLung and RespiFil Networks.

Respiration. 2022;101(1):34-45
Fibrose pulmonaire - FPI 02/08/23
Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort

Cottin V, Guéguen S, Nunes H, Jouneau S, Crestani B, Bonniaud P, Wemeau L, Israël-Biet D, Reynaud-Gaubert M, Gondouin A, Cadranel J, Marchand-Adam S, Chevereau M, Dufaure-Garé I, Amselem S, Clément A; and the RaDiCo team.

Adv Ther. 2021 Nov 10
Fibrose pulmonaire - FPI 02/08/23
Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss

Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Yang M, Morgenthien E, Kirchgaessler KU, Cottin V.

Respiration. 2021 Oct 5:1-13.
Fibrose pulmonaire - FPI 02/08/23
The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary FibrosisBrouillon auto

Zinellu A, Collu C, Nasser M, Paliogiannis P, Mellino S, Zinellu E, Traclet J, Ahmad K, Mangoni AA, Carru C, Pirina P, Fois AG, Cottin V.

J Clin Med. 2021 Sep 14;10(18):4134.
Fibrose pulmonaire - FPI 02/08/23
Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort

Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort Cottin V, Gueguen S, Jouneau S, Nunes H, Crestani B, Bonniaud P, Wémeau-Stervinou L, Reynaud-Gaubert M, Israël-Biet D, Cadranel J, Marchand-Adam S, Quétant S, Hirschi S, Montani D, Gamez AS, Chevereau M, Dufaure-Garé I, Amselem S, Clement A; OrphaLung and RespiFil Networks.

Respiration. 2021 Sep 2:1-12.
Fibrose pulmonaire - FPI 02/08/23
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD trial investigators.

Eur Respir J. 2021 Sep 2:2004538.
Fibrose pulmonaire - FPI 02/08/23
Inhibition of the Arp2/3 complex represses human lung myofibroblast differentiation and attenuates bleomycin-induced pulmonary fibrosis

Mergault C, Lisée F, Tiroille V, Magnien M, Parent C, Lenga Mabonda W, Sizaret D, Jaillet M, Crestani B, Marchand-Adam S, Plantier L.

Br J Pharmacol. 2021 Aug 28.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Breath-holding and tidal breathing nasal NO to screen children for Primary Ciliary Dyskinesia

Motile cilia and airway disease

Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study

Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort

Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort

Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss

The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary FibrosisBrouillon auto

Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

Inhibition of the Arp2/3 complex represses human lung myofibroblast differentiation and attenuates bleomycin-induced pulmonary fibrosis